Enigma Antibody (H-7): sc-390330

Enigma Antibody (H-7) is a mouse monoclonal IgG3 antibody that detects Enigma in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Enigma, also known as PDLIM7 or LMP1, is a 457 amino acid protein that plays a crucial role in cellular scaffolding and protein assembly, particularly in skeletal muscle and other tissues. Anti-Enigma antibody (H-7) recognizes a unique structure featuring three LIM zinc-binding domains and one PDZ domain, which facilitate function as an adaptor protein, linking various signaling molecules to actin filaments. This interaction is vital for maintaining cytoskeleton integrity and ensuring proper cellular signaling pathways. Enigma (H-7) antibody targets a protein implicated in bone formation processes, including both direct and endochondral ossification, highlighting importance in skeletal development and repair mechanisms. The presence of six isoforms of Enigma, resulting from alternative splicing, further underscores the complexity of regulatory roles in different biological contexts. With broad species reactivity and versatile applications, Enigma monoclonal antibody (H-7) serves as an essential tool for researchers studying these intricate functions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Enigma Antibody (H-7) References:

1. Loss of the cytoskeletal protein Pdlim7 predisposes mice to heart defects and hemostatic dysfunction.  |  Krcmery, J., et al. 2013. PLoS One. 8: e80809. PMID: 24278323
2. Phenotypic Modulation of Smooth Muscle Cells in Atherosclerosis Is Associated With Downregulation of LMOD1, SYNPO2, PDLIM7, PLN, and SYNM.  |  Perisic Matic, L., et al. 2016. Arterioscler Thromb Vasc Biol. 36: 1947-61. PMID: 27470516
3. Pdlim7 Regulates Arf6-Dependent Actin Dynamics and Is Required for Platelet-Mediated Thrombosis in Mice.  |  Urban, AE., et al. 2016. PLoS One. 11: e0164042. PMID: 27792740
4. PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence.  |  Klein, ME., et al. 2018. Oncogene. 37: 5066-5078. PMID: 29789718
5. PDLIM7 Synergizes With PDLIM2 and p62/Sqstm1 to Inhibit Inflammatory Signaling by Promoting Degradation of the p65 Subunit of NF-κB.  |  Jodo, A., et al. 2020. Front Immunol. 11: 1559. PMID: 32849529
6. TPM2 attenuates progression of prostate cancer by blocking PDLIM7-mediated nuclear translocation of YAP1.  |  Wu, Z., et al. 2023. Cell Biosci. 13: 39. PMID: 36823643
7. Cancer-derived mutation in the OGA stalk domain promotes cell malignancy through dysregulating PDLIM7 and p53.  |  Hu, CW., et al. 2023. Res Sq.. PMID: 36993758
8. H3K27 acetylation activated-PDLIM7 promotes castration-resistant prostate cancer progression by inducing O-Glycosylation of YAP1 protein.  |  Liu, Q., et al. 2024. Transl Oncol. 40: 101830. PMID: 38056280
9. PDLIM7 Promotes Tumor Metastasis in Papillary Thyroid Carcinoma via Stabilizing Focal Adhesion Kinase Protein.  |  Yang, F., et al. 2024. Thyroid. 34: 598-610. PMID: 38243825
10. OGA mutant aberrantly hydrolyzes O-GlcNAc modification from PDLIM7 to modulate p53 and cytoskeleton in promoting cancer cell malignancy.  |  Hu, CW., et al. 2024. Proc Natl Acad Sci U S A. 121: e2320867121. PMID: 38838015

The preferred Enigma antibody is Enigma Antibody (H-12): sc-398100.